Largest positions
| Issuer | Class | Value | Share |
|---|---|---|---|
| Roivant Sciences LtdSHS | SHS | $283,860,642 | 44.0% |
| Revolution Medicines Inc.COM | COM | $51,689,280 | 8.0% |
| Mirum Pharmaceuticals Inc.COM | COM | $30,496,735 | 4.7% |
| Abivax SASPONSORED ADS | SPONSORED ADS | $27,518,190 | 4.3% |
| Beone Medicines LtdSPONSORED ADS | SPONSORED ADS | $25,652,999 | 4.0% |
| Pharvaris N VCOM | COM | $23,210,407 | 3.6% |
| Argenx SESPONSORED ADR | SPONSORED ADR | $21,338,710 | 3.3% |
| United Therapeutics Corp. DelCOM | COM | $20,112,730 | 3.1% |
| Belite Bio Inc.SPONSORED ADS | SPONSORED ADS | $16,938,350 | 2.6% |
| Cogent Biosciences Inc.COM | COM | $16,447,500 | 2.5% |
| Dbv Technologies S ASPONSORED ADS | SPONSORED ADS | $14,915,374 | 2.3% |
| Xenon Pharmaceuticals Inc.COM | COM | $13,279,200 | 2.1% |
| Biontech SESPONSORED ADS | SPONSORED ADS | $12,508,618 | 1.9% |
| Arcus Biosciences Inc.COM | COM | $10,969,314 | 1.7% |
| Enliven Therapeutics Inc.COM | COM | $10,784,375 | 1.7% |
| Dianthus Therapeutics Inc.COM | COM | $10,527,840 | 1.6% |
| Allogene Therapeutics Inc.COM | COM | $10,504,000 | 1.6% |
| Eyepoint Inc.COM NEW | COM NEW | $10,296,000 | 1.6% |
| Arcutis Biotherapeutics Inc.COM | COM | $9,701,400 | 1.5% |
| C4 Therapeutics Inc.COM STK | COM STK | $7,513,166 | 1.2% |
| Inventiva SAADS | ADS | $7,435,906 | 1.2% |
| Kymera Therapeutics Inc.COM | COM | $5,446,825 | 0.8% |
| Faeth Therapeutics Inc.COM NEW | COM NEW | $4,376,250 | 0.7% |
- Class
- SHS
- Share
- 44.0%
- Class
- COM
- Share
- 8.0%
- Class
- COM
- Share
- 4.7%
- Class
- SPONSORED ADS
- Share
- 4.3%
- Class
- SPONSORED ADS
- Share
- 4.0%
- Class
- COM
- Share
- 3.6%
- Class
- SPONSORED ADR
- Share
- 3.3%
- Class
- COM
- Share
- 3.1%
- Class
- SPONSORED ADS
- Share
- 2.6%
- Class
- COM
- Share
- 2.5%
- Class
- SPONSORED ADS
- Share
- 2.3%
- Class
- COM
- Share
- 2.1%
- Class
- SPONSORED ADS
- Share
- 1.9%
- Class
- COM
- Share
- 1.7%
- Class
- COM
- Share
- 1.7%
- Class
- COM
- Share
- 1.6%
- Class
- COM
- Share
- 1.6%
- Class
- COM NEW
- Share
- 1.6%
- Class
- COM
- Share
- 1.5%
- Class
- COM STK
- Share
- 1.2%
- Class
- ADS
- Share
- 1.2%
- Class
- COM
- Share
- 0.8%
- Class
- COM NEW
- Share
- 0.7%
The share class is shown on a wider screen.
The 23 largest of 23 positions by value, with holdings of the same security combined. Share counts and quarter-on-quarter changes for each position are on EDGAR. View the full information table on EDGAR
This filing
- Form
- 13F-HR
- CIK
- 1819257
- File number
- 028-22927
- Options
- 0 call, 0 put
- In the 25 largest
- 100.0%
- Prior quarter
- $563,607,117 at 31 March 2026
- Positions opened
- 6
- Positions closed
- 12
Common questions
What are Patient Square Capital’s 13F holdings worth?
$645,523,811 across 23 positions for the quarter ended 30 June 2026.
What is Patient Square Capital’s largest 13F holding?
ROIVANT SCIENCES LTD (SHS) was the largest position at $283,860,642, or 44.0% of reported 13F value, as of 30 June 2026.
How concentrated is Patient Square Capital’s 13F portfolio?
The ten largest positions accounted for 80.1% of reported value and the twenty-five largest for 100.0%, across 23 positions as of 30 June 2026.
Does Form 13F show everything Patient Square Capital manages?
No. Form 13F covers only long positions in exchange-traded securities over which the manager has investment discretion, valued at quarter end. It excludes cash, most bonds, private funds, and any assets the firm does not have discretion over, so it is neither the firm's total assets nor any individual client's portfolio.
How often does Patient Square Capital file its 13F?
Every quarter. Managers file within 45 days of each quarter's end, so the figures are a snapshot that changes between filings. This page shows the quarter ended 30 June 2026.
Answered from this filing and the prior quarter's.